---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-22-000030"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:10:54.793543+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics Q3 loss $30.6M; positive Phase 2a IPF data; $215M offering closed

## Summary
- Net loss of $30.6M in Q3 2022 vs $27.0M prior year; cash & investments $360.2M, funding to mid-2025.
- Positive Phase 2a data for bexotegrast in IPF: dose-dependent improvement in FVC, QLF, and biomarkers over 12 weeks.
- Closed public offering yielding $215.4M net proceeds to fund clinical programs and operations.
- Appointed Dr. Katharine Knobil to Board; oncology IND submission expected by end of 2022.
- DSMB reviews for INTEGRIS-IPF and INTEGRIS-PSC trials recommended continuation without modification.

## SEC filing metadata
- accession: 0001746473-22-000030
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000030/0001746473-22-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000030/plrx-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-22-000030
- JSON: https://secwatch.observer/filing/0001746473-22-000030.json
- Plain text: https://secwatch.observer/filing/0001746473-22-000030.txt

## Key facts
- Earnings Releases
  PLIANT THERAPEUTICS, INC. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000030/0001746473-22-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.